Oryzon Genomics

Update in progress

ORY.MC (MCE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company developing epigenetics-based therapies for cancer, CNS disorders, and hematology. Lead programs include iadademstat (ORY-1001), a selective LSD1 inhibitor in Phase II for oncology, and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor in Phase II for CNS and psychiatric diseases. Other candidates are ORY-3001 (LSD1, preclinical) and ORY-4001 (HDAC-6 inhibitor for neurological disorders). Based in Cornellà de Llobregat, Spain, it collaborates with Columbia University and INGM Madrid and conducts CRADA-driven trials.

Company score

Sentiment: 0.32; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.17; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive